Tesamorelin monograph

Tesamorelin

Overview

Tesamorelin is a synthetic 44-amino-acid analog of human growth hormone–releasing hormone used clinically to reduce excess abdominal/visceral fat in adults with HIV-associated lipodystrophy. It is not a bodybuilding staple with robust evidence; its real clinical niche is narrow, and off-label performance use remains investigational and legally/antidoping problematic. Published sources describe it as a GHRH analog with limited human pharmacokinetic data and a short plasma half-life after subcutaneous dosing.

Pharmacokinetics & Mechanism

• Class: Synthetic growth hormone-releasing hormone (GHRH) analog peptide
• Mechanism of action: Tesamorelin binds the growth hormone–releasing hormone receptor (GHRHR) on pituitary somatotrophs, stimulating pulsatile endogenous growth hormone release and downstream hepatic IGF-1 production. The net effect is GH-axis activation rather than direct exogenous growth hormone replacement. In clinical trials, this shifts body composition by reducing visceral adipose tissue, but it does not establish a reliable hypertrophy or performance-enhancement effect in healthy athletes.
• Target(s): Primary target: growth hormone–releasing hormone receptor (GHRHR) in the anterior pituitary. Downstream pathway: increased endogenous GH secretion, increased hepatic IGF-1, and GH/IGF-1 signaling effects on lipolysis and fat partitioning. No direct androgenic, anabolic steroid, or myostatin-targeting activity is established.
• Route(s) of administration: Subcutaneous injection only. No oral, intranasal, or intravenous clinical route is established for approved use.
• Onset: GH/IGF-1 axis effects begin after injection, but body-composition changes are gradual over weeks to months. Acute endocrine response occurs rapidly; visible physique changes are not immediate.
• Half-life: Short plasma half-life after subcutaneous dosing; published human label-level summaries commonly describe it as very short, around minutes rather than hours. Exact values vary by study/assay and are not always reported consistently in public summaries, so for coaching purposes the safest statement is: short half-life, rapid clearance, once-daily dosing in approved use. No long-acting/DAC tesamorelin product is established in the approved literature.
• Metabolism / clearance: Peptide catabolism via proteolytic degradation to amino acids/short peptides; no clinically important CYP-mediated metabolism is established. Clearance is rapid after subcutaneous administration, consistent with a short peptide hormone analog. Specific human metabolic pathways are not well characterized in public labeling beyond general peptide degradation.